Health and Healthcare
Gilead Sciences and Celgene Score Major Drug Wins
Published:
Last Updated:
Celgene Corp. (NASDAQ: CELG) is surging by 9% to $78.00, versus a 52-week high of $81.24. With a prior market cap of $30.2 billion, this is more than $3 billion of added market value. The news is that a late-stage trial showed that Abraxane significantly improved the lifespan of pancreatic cancer patients. The company did not offer a formal number, but this was for a combination therapy.
Gilead Sciences Inc. (NASDAQ: GILD) is up more than 10% to $72.00, a new 52-week high, and we would note that the market cap was $49.2 billion before this news. The value add is close to $5 billion in additional market capitalization. The news behind the move is that a combination of its Hepatitis C therapies cured the virus in 100% of patients in a trial. This news was part of the American Association for the Study of Liver Diseases in Boston.
With the value being added to the market in these two stocks, the market is indicating the potential for a blockbuster drug status on each bit of news.
JON C. OGG
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.